IL202132A - Phenylalanine ammonia-liaz prokaryotic variants, preparations containing them and methods of use in these compositions - Google Patents

Phenylalanine ammonia-liaz prokaryotic variants, preparations containing them and methods of use in these compositions

Info

Publication number
IL202132A
IL202132A IL202132A IL20213209A IL202132A IL 202132 A IL202132 A IL 202132A IL 202132 A IL202132 A IL 202132A IL 20213209 A IL20213209 A IL 20213209A IL 202132 A IL202132 A IL 202132A
Authority
IL
Israel
Prior art keywords
compositions
lyase
variants
methods
phenylalanine ammonia
Prior art date
Application number
IL202132A
Other languages
English (en)
Hebrew (he)
Other versions
IL202132A0 (en
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL202132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of IL202132A0 publication Critical patent/IL202132A0/en
Publication of IL202132A publication Critical patent/IL202132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL202132A 2007-05-25 2009-11-15 Phenylalanine ammonia-liaz prokaryotic variants, preparations containing them and methods of use in these compositions IL202132A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
PCT/US2008/006661 WO2008153776A1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (2)

Publication Number Publication Date
IL202132A0 IL202132A0 (en) 2010-06-16
IL202132A true IL202132A (en) 2017-06-29

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202132A IL202132A (en) 2007-05-25 2009-11-15 Phenylalanine ammonia-liaz prokaryotic variants, preparations containing them and methods of use in these compositions

Country Status (29)

Country Link
US (1) US7534595B2 (enExample)
EP (2) EP2152868B1 (enExample)
JP (1) JP5670183B2 (enExample)
KR (2) KR101603796B1 (enExample)
CN (1) CN101842482B (enExample)
AR (2) AR066716A1 (enExample)
AU (1) AU2008263190B2 (enExample)
BR (1) BRPI0811267B8 (enExample)
CA (1) CA2687450C (enExample)
CL (1) CL2008001497A1 (enExample)
CY (2) CY1116894T1 (enExample)
DK (1) DK2152868T3 (enExample)
EA (1) EA018443B1 (enExample)
ES (1) ES2551315T3 (enExample)
HR (1) HRP20151268T1 (enExample)
HU (2) HUE025784T2 (enExample)
IL (1) IL202132A (enExample)
LT (1) LTC2152868I2 (enExample)
LU (1) LUC00133I2 (enExample)
MX (1) MX2009012453A (enExample)
MY (1) MY151413A (enExample)
NL (1) NL301011I2 (enExample)
NO (1) NO2019037I1 (enExample)
PE (1) PE20090315A1 (enExample)
PL (1) PL2152868T3 (enExample)
PT (1) PT2152868E (enExample)
SI (1) SI2152868T1 (enExample)
TW (1) TWI418633B (enExample)
WO (1) WO2008153776A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
EP3222288A1 (en) * 2012-07-27 2017-09-27 University of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
PL2986722T3 (pl) 2013-04-18 2019-10-31 Codexis Inc Skonstruowane polipeptydy amoniakoliazy fenyloalaniny
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP3145536B1 (en) 2014-04-16 2021-10-27 Codexis, Inc. Engineered tyrosine ammonia lyase
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(一)
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
CN109844127B (zh) * 2016-08-30 2023-09-19 三菱化学株式会社 突变型酶的制造方法及突变型醇酰基转移酶
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
AU2018217495B2 (en) * 2017-02-13 2021-03-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
EP3820833A4 (en) * 2018-07-12 2022-08-03 Codexis, Inc. MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
BR112022003705A2 (pt) 2019-08-30 2022-05-24 Codexis Inc Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
EP4103711A4 (en) 2020-02-04 2024-02-28 Codexis, Inc. Engineered leucine decarboxylases
WO2021168060A1 (en) * 2020-02-19 2021-08-26 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
JP2023539634A (ja) 2020-08-28 2023-09-15 コデクシス, インコーポレイテッド 操作されたアミラーゼバリアント
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
WO2022245924A1 (en) * 2021-05-19 2022-11-24 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Syntis Bio, Inc. Engineered methionine gamma lyase variants
WO2023044381A1 (en) * 2021-09-16 2023-03-23 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ,インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
WO2025106759A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1994013817A1 (en) 1992-12-04 1994-06-23 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in antiviral and anticancer therapy
JP2930723B2 (ja) 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ,インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280924A2 (en) 2000-04-14 2003-02-05 University of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
EP1309705B1 (en) * 2000-07-25 2012-02-15 Immunomedics Inc. Multivalent target binding protein
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
JP4722396B2 (ja) 2002-02-26 2011-07-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 遺伝要素の組換え方法
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ(faah)の結晶形
AU2004247737B2 (en) * 2003-06-11 2009-04-23 Wyeth Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005286763A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
LTC2152868I2 (lt) 2020-09-25
EP2657335A1 (en) 2013-10-30
AU2008263190A1 (en) 2008-12-18
CN101842482A (zh) 2010-09-22
SI2152868T1 (sl) 2015-12-31
PL2152868T3 (pl) 2016-01-29
US20080008695A1 (en) 2008-01-10
LUC00133I1 (enExample) 2019-10-16
LTPA2019517I1 (lt) 2019-10-25
CA2687450A1 (en) 2008-12-18
KR101603796B1 (ko) 2016-03-17
MY151413A (en) 2014-05-30
KR20100024437A (ko) 2010-03-05
DK2152868T3 (en) 2015-11-16
LUC00133I2 (enExample) 2020-07-16
WO2008153776A1 (en) 2008-12-18
AU2008263190B2 (en) 2014-04-17
JP2010529835A (ja) 2010-09-02
ES2551315T3 (es) 2015-11-18
HUS1900049I1 (hu) 2019-11-28
EP2152868A1 (en) 2010-02-17
CN101842482B (zh) 2014-10-22
WO2008153776A8 (en) 2009-07-30
US7534595B2 (en) 2009-05-19
CY2019039I1 (el) 2020-05-29
PT2152868E (pt) 2015-11-13
AR110834A2 (es) 2019-05-08
BRPI0811267B1 (pt) 2020-11-10
JP5670183B2 (ja) 2015-02-18
AR066716A1 (es) 2009-09-09
CL2008001497A1 (es) 2009-01-09
IL202132A0 (en) 2010-06-16
CY1116894T1 (el) 2017-04-05
NL301011I2 (nl) 2020-05-13
EP2152868B1 (en) 2015-09-02
TWI418633B (zh) 2013-12-11
HUE025784T2 (en) 2016-05-30
TW200902052A (en) 2009-01-16
CA2687450C (en) 2019-03-26
MX2009012453A (es) 2010-01-25
HK1135141A1 (zh) 2010-05-28
HRP20151268T1 (hr) 2015-12-18
CY2019039I2 (el) 2020-05-29
EA200970980A1 (ru) 2010-04-30
NL301011I1 (nl) 2019-10-16
EA018443B1 (ru) 2013-08-30
BRPI0811267B8 (pt) 2021-05-25
BRPI0811267A2 (pt) 2014-10-07
KR20150038753A (ko) 2015-04-08
PE20090315A1 (es) 2009-03-19
NO2019037I1 (no) 2019-10-16

Similar Documents

Publication Publication Date Title
HUS1900049I1 (hu) Prokarióta fenilalanin ammónia-liáz készítmények és azok alkalmazási eljárásai
SI2175875T1 (sl) Sestavki iz prokariontske fenilalanin amonij-liaze in metode za zdravljenje raka z uporabo le-teh sestavkov
IL223784A (en) Antimicrobial peptide, preparations and methods of use
ZA201001300B (en) Antigen-asjuvant compositions and methods
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
GB0717864D0 (en) Peptide sequences and compositions
IL238404A0 (en) Preparations and methods to prevent influenza
GB0819530D0 (en) Methods and compositions
PL2081499T3 (pl) Ograniczanie kurczy mięśni
GB0721291D0 (en) Methods and compositions
GB0601143D0 (en) Uses, methods and compositions
IL197528A0 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
GB0706077D0 (en) Methods, Compositions and uses thereof
GB0719526D0 (en) Compositions and methods
GB0605247D0 (en) Compositions and methods for immunisation
PT2264060E (pt) Composições e processos para inibição da adesão viral
GB0617171D0 (en) Novel compositions and methods
GB2453860B (en) Ionizing-radiation-responsive compositions,methods and systems
IL207174A0 (en) Peptides, compositions, and uses thereof
AU2014200650C1 (en) Anti-CXCR1 compositions and methods
GB0723775D0 (en) Methods and compositions
GB0717683D0 (en) Compositions and methods
GB0607565D0 (en) Methods and compositions
GB0625230D0 (en) Compositions and methods
HK1132166A (en) Limiting muscle cramps

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed